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Abstract
Background: When combined with a clinical outcome variable, the size, complexity and nature of mass-spectrometry
proteomics data impose great statistical challenges in the discovery of potential disease-associated biomarkers. The
purpose of this study was thus to evaluate the effectiveness of different statistical methods applied for urinary proteomic
biomarker discovery and different methods of classifier modelling in respect of the diagnosis of coronary artery disease in
197 study subjects and the prognostication of acute coronary syndromes in 368 study subjects.
Results: Computing the discovery sub-cohorts comprising 2 3= of the study subjects based on the Wilcoxon rank sum test,
t-score, cat-score, binary discriminant analysis and random forests provided largely different numbers (ranging from 2 to
398) of potential peptide biomarkers. Moreover, these biomarker patterns showed very little overlap limited to fragments
of type I and III collagens as the common denominator. However, these differences in biomarker patterns did mostly not
translate into significant differently performing diagnostic or prognostic classifiers modelled by support vector machine,
diagonal discriminant analysis, linear discriminant analysis, binary discriminant analysis and random forest. This was even
true when different biomarker patterns were combined into master-patterns.
Conclusion: In conclusion, our study revealed a very considerable dependence of peptide biomarker discovery on
statistical computing of urinary peptide profiles while the observed diagnostic and/or prognostic reliability of classifiers
was widely independent of the modelling approach. This may however be due to the limited statistical power in classifier
testing. Nonetheless, our study showed that urinary proteome analysis has the potential to provide valuable biomarkers
for coronary artery disease mirroring especially alterations in the extracellular matrix. It further showed that for a
comprehensive discovery of biomarkers and thus of pathological information, the results of different statistical methods
may best be combined into a master pattern that then can be used for classifier modelling.
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Background
In recent years, the non-parametric Wilcoxon rank sum
test (WT) based statistical analysis of urine proteome
profiles provided by capillary zone electrophoresis on-
line coupled to electrospray ionization time-of-flight
mass spectrometry (CE-MS) lead to the discovery of bio-
marker patterns e.g. for the diagnosis of coronary artery
disease (CAD) [1]. In these studies, support vector
machine (SVM) modelling was used to establish disease
classifiers based on these biomarker patterns. However,
it is unclear if this is the best possible approach. Besides
critical technical aspects using CE-MS and study design
[2], biomarker detection in these urine proteome profiles
depends on computing statistical analysis of high-
dimensional datasets while dealing with often limited
statistical power due to rather small sample sizes. A
small sample size in comparison to the number of vari-
ables causes statistical algorithms to overfit the data.
This presents challenges for the statistical analysis that
must be addressed as good as possible to yield effective
and reliable biomarkers.
The purpose of this study was to compare the effective-
ness of different statistical methods for urinary biomarker
discovery as well as the performance of classifiers estab-
lished by different modelling approaches in respect of the
diagnosis of coronary artery disease in 197 study subjects
and the prognostication of acute coronary syndromes
in 368 study subjects. For biomarker discovery and
modelling as well as validation of the classifier perform-
ance, study subjects were assigned to sub-cohorts. The
statistical methods for biomarker discovery included
correlation-adjusted t-scores (cat-score), introduced by
Zuber and Strimmer [3], to address potential correla-
tions among peptides/proteins.
Methods
Ethics approval and consent to participate
All studies contributing samples to this new study were
originally approved by local ethics committees, are in
keeping with the principles of the Declaration of Helsinki
and all participants originally gave written informed con-
sent. All datasets derived from studies mentioned above
were pooled from the database at Mosaiques Diagnostics
GmbH, Hanover, Germany. The current study was ap-
proved by the local ethics committee at the Medical
School Hanover, approval number 3184-2016.
Study population
The different computational statistical methods applied
for the discovery of proteomic biomarkers were compared
in a combined multi-centre cohort. This cohort included
individuals with known symptomatic or unknown asymp-
tomatic CAD with and without an incident of acute myo-
cardial infarction (AMI) within up to 11 years post urine
sampling and randomly selected suitable controls without
CAD or an AMI from separate studies conducted in
Australia, Europe and North America.
Urine proteome datasets of cases and controls were
compiled from four cohorts. The first cohort comprised
30 patients with CAD characterized by stable angina in-
cluding chest pain and with at least one coronary artery
stenosis ≥75% of the artery lumen and 30 controls with-
out any angiographic evidence of CAD. It originated
from the Diagnosis of Coronary Artery Disease with
Urine proteomics (DICADU) study performed at the
Golden Jubilee National Hospital, Clydebank, UK [4].
The second cohort consisted of 71 proteome profile
datasets from patients with severe CAD requiring elect-
ive coronary artery bypass grafting (CABG) and 66
healthy volunteers without evidence of CAD as controls
from the VAScular function in Coronary Artery Bypass
(VASCAB) study performed at the Glasgow BHF Cardio-
vascular Research Centre [5]. The third cohort included
155 patients with an incident AMI and 155 subjects
without a CV event during a follow-up period of 11 years
from the Australian Diabetes, Obesity and Lifestyle
(AusDiab) study [6]. The fourth cohort comprised 5 pa-
tients with an incident AMI and 53 subjects without a
CV event during a follow-up period of 6 years from the
Coronary Artery Calcification in Type 1 Diabetes
(CACTI) study [7].
From the AusDiab and CACTI cohorts, 40 (25.0%) out
of the 160 patients with an incident AMI event during the
observation period (cases) had a previous history of angina
pectoris and/or AMI. In the other 120 patients, AMI was
the first cardiac event. Out of the 208 subjects without an
event during follow-up (controls), 17 (8.2%) had previous
symptoms of angina pectoris and/or an AMI.
Definition of coronary artery disease and assessment of
outcome
CAD was confirmed by coronary angiography. In
addition, four incident outcomes were considered, non-
fatal AMI (N = 60), fatal AMI (N = 95), AMI without
information on fatality (N = 5) and no AMI (N = 208)
during a follow-up time up to 11 years after urine sam-
pling. AMI was defined as having at least two of the fol-
lowing three features: (i) a typical clinical presentation,
(ii) electrocardiography changes and (iii) cardiac en-
zymes rises (including creatine kinase and troponin)
compliant with World Health Organisation MONICA
criteria for myocardial infarction. Fatal AMI was defined
from death certificate coding, using International Classi-
fication of Diseases Version 10 (ICD-10) codes I20-I25.
Proteome profiles
All urine proteome profiles originating from previous
studies [5–8] were pooled from our database at Mosaiques
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Diagnostics GmbH, Hanover, Germany. The proteome
profiles were based on CE-MS analysis performed by
Mosaiques Diagnostics GmbH, and they had passed all
quality control criteria [8]. Briefly, sample storage and
preparation followed established standard operating pro-
cedures as described previously [9]. CE-MS analyses also
followed standard operating procedures using a P/ACE
MDQ capillary electrophoresis system (Beckman Coulter,
Fullerton, USA) on-line coupled to a microTOF MS (Bru-
ker Daltonics, Bremen, Germany) as described previously
[9, 10]. Accuracy, precision, selectivity, sensitivity, repro-
ducibility, and stability of the CE-MS measurements were
demonstrated elsewhere [9]. Mass spectral peaks repre-
senting identical molecules at different charge states were
deconvoluted into single masses using MosaiquesVisu
software [11]. For normalization of analytical and urine
dilution variances, signal intensities were normalized rela-
tive to 29 “housekeeping” peptides [12, 13]. All detected
peptides were deposited, matched, and annotated in a
Microsoft SQL database allowing further statistical ana-
lysis [14] and sequenced as described elsewhere [15, 16].
Cohorts for the detection of biomarkers
In each of the 4 study cohorts, subjects were assigned ei-
ther to peptide biomarker discovery or validation set by
a 2 3= to 1 3= ratio, respectively, as presented in Table 1.
The discovery datasets were further grouped for the dis-
covery of potential biomarkers for the diagnosis of sig-
nificant to severe CAD (CADD; cohorts DICADU and
VASCAB), the prognostication of future incidents of
AMI (AMIP; cohorts AusDiab and CACTI) and the
combined diagnosis of CAD and prognostication of its
outcome as an AMI (ACD; cohorts DICADU, VASCAB,
AusDiab and CACTI) (Fig. 1). None of the subjects used
as controls for peptide biomarker discovery had a known
cardiovascular condition.
Statistical procedures for the discovery of biomarkers
(1) Non-parametric Wilcoxon rank sum test (WT): In
WT analysis only peptides that were present at a frequency
of 70% or higher in either case or control group were con-
sidered as potential biomarkers. The false discovery rate
adjustments of Benjamini-Hochberg [17] were employed to
correct for multiple testing. A P-value < 0.05 was consid-
ered to be statistically significant. (2) t-score: The t-statistic
was used to identify differentially expressed peptides. Local
false discovery rate was applied to account for multiple test-
ing. (3) Correlation adjusted t-score: The previous two
scores do not take into account that different peptides in
the high-dimensional proteomic datasets may not be inde-
pendent of each other, e.g. if peptides originate from the
same protein. To this end, [3] we introduced the
correlation-adjusted t-score (cat score). The p-values were
adjusted using the local false discovery rate. (4) Random
forests (RF): Random forests are used extensively in the lit-
erature. Diaz-Uriarte and de Andres [18] introduced a
method that combines RF and variable selection. This
method was applied in the gene selection context and is
extended in the proteomics context in this paper. The con-
tribution of the work of Diaz-Uriarte and de Andres was
two-fold: First, they introduce an iterative procedure to per-
form variable selection. At each step and for each tree, they
discarded the features with the smallest variable importance
factor. Then, they re-grew their tree with the remaining
variables. This can also be seen as a backward elimination
procedure. Their second contribution was to evaluate the
stability of their results using bootstrap. Calle et al. [19]
stated that the method of Diaz-Uriarte and de Andres
might not work well when the number of control and cases
is unbalanced.
Classifier modelling
In addition to the different statistical attempts for bio-
marker discovery, we also assessed different methods for
disease classifier modelling in respect to the diagnosis of
significant to severe CAD (CADD), the prognostication
of future incidents of AMI (AMIP) and the combined
diagnosis of CAD and prognostication of its outcome as
an AMI (ACD). (1) Linear Discriminant Analysis
(LDA): Linear discriminant analysis reduces the dimen-
sionality of the data, while preserving the structure that
discriminates between the different groups. LDA as-
sumes that the data have been generated from a mixture
of multivariate normal distributions, where the covari-
ance matrix is the same across the different components.
However the assumption of normality is not restrictive.
Since the number of proteins is much larger than the
number of samples, regularisation methods have to be
applied. This is done in order to avoid computational
problems with the matrix operations. Ahdesmaeki and
Strimmer [20] utilised James-Stein shrinkage methods to
address the problem. An additional benefit from using
this procedure is that one can obtain analytically the
regularisation parameters without having to employ
cross-validation. Feature selection is performed using
the cat-score. (2) Diagonal Discriminant Analysis
(DDA): Diagonal discriminant analysis is a special case
Table 1 Numbers of study subjects in Cohorts for biomarker
discovery and validation
Cohort Discovery Validation Validation
1 (0–5 years)
Validation 2
(5–11 years)
DICADU 39 21
VASCAB 93 44
AusDiab 144 74 92
CACTI 6 2 50
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of LDA. DDA assumes that each feature is independent
(i.e. the covariance matrix has just diagonal elements).
This assumption, although simplistic, has been proven to
work well even in high-dimensional settings. t-score is the
optimal statistic to perform feature selection in this set-
ting. (3) Binary Discriminant Analysis (BDA): Gibb and
Strimmer [21] developed a binary discriminant analysis
method for the identification of differential protein ex-
pression. As the name suggests, the protein intensities
were converted to binary according to a data-dependent
thresholding procedure. Since the task is linked with the
construction of a classifier, informative proteins were se-
lected based on their ability to distinguish between the
two groups. A limitation of the method is that no multiple
testing corrections can be applied. (4) Random forests
(RF): Another popular machine learning method used for
classification is random forests (RF). The method was in-
troduced by [22] and belongs to the class of ensemble
learning classifiers. A large number of classification trees
are grown and their results are averaged. In this context,
all the variables obtained from the method of Diaz-Uriarte
and de Andres are plugged in a RF classifier. (5) Support
vector machine modelling: Support vector machine
(SVM) is a supervised learning algorithm for two-group
classification belonging to the family of margin-based clas-
sifiers[23]. Compared with other supervised classification
algorithms (Logistic regression, K-Nearest Neighbours,
Naïve Bayes, Decision Tree, Discriminant analysis), SVM
has the highest potential to perform well in terms of aver-
age classification accuracy, time required for training and
memory usage on high dimensional noisy data typical of
biomedical datasets [24]. As a result, SVM is widely used
for a number of machine learning applications in the life
sciences, including for biomarker discovery in proteomics
datasets [25]. Thus, identified peptide biomarkers were
combined into single multi-dimensional classifiers, using
the support-vector machine based MosaCluster software,
version 1.7.0 [26]. MosaCluster calculates classification
scores based on the amplitudes of the biomarkers selected.
Classification is performed by determining the Euclidian
distance (defined as the SVM classification score) of the
vector to a maximal margin hyperplane.
Fig. 1 Study design for biomarker identification and validation. CADD, coronary artery disease diagnosis; AMIP, acute myocardial infarction
prognostication; ACD, combined coronary artery disease diagnosis and outcome (AMI) prognostication; WT, non-parametric Wilcoxon rank sum
test, BDA, binary discriminant analysis; RF, random forests; SVM, support vector machine; DDA, diagonal discriminant analysis; LDA, linear
discriminant analysis
Stanley et al. BMC Bioinformatics  (2016) 17:496 Page 4 of 10
Library for Support Vector Machines
For this work, the Library for Support Vector Machines
(LIBSVM) was used [27]. LIBSVM is an integrated,
open source machine-learning library that implements
the Sequential minimal optimization (SMO) algorithm
for SVM training [28]. Input datasets consisted of
urinary peptidomic readouts from combined patient co-
horts as described in the methods section above. The
steps followed to perform the SVM modelling from
these input datasets were as follows: a) for a given pa-
tient cohort, define the binary response variable against
which the model is developed; b) assign cohort mem-
bers into balanced discovery (training) and validation
(test) sets; c) prepare the peptidomics data (SVM fea-
tures) through transformation into the correct non-
categorical format (vector of real numbers), and scaling
to avoid attributes in greater numeric ranges dominat-
ing those in smaller numeric ranges; d) configure the
SVM software through selection of an appropriate ker-
nel, and optimization of the kernel parameters; radial
basis function kernel was used because of its accurate
and reliable performance, and kernel parameters (pen-
alty parameter on the training error, C, and smoothness
parameter, γ, were optimized through 10-fold cross
validation [29, 30]; e) run the SVM software on the
training set to generate an initial classifier; f ) iteratively
exclude peptides features with the lowest contribution
(f-score) to the SVM until the optimal classifier in
terms of receiver operating characteristic area under
the curve (ROC-AUC) with the smallest number of
peptides is obtained. This is a “wrapper type” approach
to feature selection [31]. The accuracy of the initial
SVM classifier from all peptide features and the final
classifier following feature selection were calculated
using the validation (test) sets.
Statistical methods and sample classification
We determined optimal threshold criterion for the classi-
fiers to differentiate control individuals from individuals
with CAD and/or individuals who experienced an incident
AMI based on maximized Younden’s index determined by
Receiver Operating Characteristic (ROC) analysis carried
out in MedCalc version 12.7.3.0 (MedCalc Software,
Mariakerke, Belgium, https://www.medcalc.org/). The
ROC plot was obtained and the area under the ROC curve
(AUC) was evaluated. Areas under the curve (AUC) and
their 95% confidence intervals (CI) were determined based
on the optimal threshold criterion.
Results
Biomarker discovery
Biomarkers were detected by computing the grouped
proteomic biomarker discovery datasets for CADD,
AMIP and ACD mentioned in the methods section
(Table 1) based on WT, t-score, cat score, BDA or RF
(Fig. 1). Demographic and clinical characteristics of
these selected cases and controls are presented in
Table 2. The biomarkers detected by the different statis-
tical approaches are listed in Additional file 1: Table S1
for CADD, Table S2 for AMIP and Table S3 for ACD.
These biomarkers were selected based on a P-value <
0.05 (WT) or local false discovery rate <0.2 (t-score and
cat score), while the stability of the results obtained with
RF was checked by performing bootstrap (RF).
Firstly, we observed that the numbers of potential pep-
tide biomarkers for CADD, AMIP and ACD differed
greatly between the different discovery methods. Besides
the numbers of potential peptide biomarkers also the kind
of potential biomarkers differed. Out of in total 444 pep-
tide biomarkers discovered for CADD, only four were
detected by all biomarker discovery approaches (marked
Table 2 Demographic and clinical data of subjects in the biomarker discovery cohort
Parameter DICADU
control
DICADU
case
VASCAB
control
VASCAB
case
AusDiab
control
AusDiab
case
CACTI
control
CACTI
case
N 20 19 46 47 72 72 3 3
Age 56 ± 7 54 ± 6 63 ± 8 63 ± 9 65 ± 11 65 ± 11 43 ± 4 44 ± 3
Female (%) 52.6 40.0 23.6 23.4 38.9 37.5 33.3 33.3
Gensini plaque score 0 ± 0 42 ± 28 0 ± 0 80 ± 31 n.a. n.a. n.a. n.a.
Diabetes (%) 5.0 21.1 0 23.4 8.3 27.8 100 100
Current smoker (%) 20.0 21.1 4.3 6.4 4.2 22.2 33.3 33.3
Systolic blood pressure (mm Hg) 137 ± 18 133 ± 15 140 ± 17 139 ± 25 136 ± 19 147 ± 21 111 ± 10 122 ± 14
Diastolic blood pressure (mm Hg) 81 ± 10 78 ± 10 82 ± 11 79 ± 13 70 ± 11 76 ± 11 80 ± 10 87 ± 10
Total cholesterol (mmol/l) 5.2 ± 1.2 5.9 ± 0.3 5.6 ± 1.1 4.1 ± 0.9 6.2 ± 1.1 6.0 ± 1.2 4.8 ± 0.4 5.4 ± 0.7
HDL cholesterol (mmol/l) 1.2 ± 0.3 1.2 ± 0.3 1.5 ± 0.4 1.2 ± 0.3 1.5 ± 0.4 1.2 ± 0.4 1.3 ± 0.5 1.3 ± 0.6
Trigycerides (mmol/l) 2.0 ± 1.0 1.8 ± 0.8 1.6 ± 0.9 2.2 ± 1.0 n.a. n.a. 1.1 ± 0.8 1.1 ± 0.5
n.a. not available; Diabetes, type 2 except in CACTI where it is type I
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in grey) (Fig. 2). For 3 of these sequence information was
available revealing that two peptides originated from type
III collagen and one originated from type I collagen. The
biggest overlap was observed between t-score (N = 94 pep-
tides) and BDA (N = 65 peptides) based biomarker discov-
ery reaching an overlap of 44 peptides. In AMIP analysis,
the numbers of discovered peptide biomarkers were much
lower. The t-score analysis did not identify any bio-
markers. Moreover, in AMIP no biomarkers were com-
monly discovered with the remaining 4 methods. In ACD
only one potential biomarker was detected by all discovery
approaches out of 171 potential biomarkers discovered in
total. This biomarker, a type III collagen fragment with
the sequence SpGERGETGPpGP, was also one of the four
biomarkers commonly discovered for CADD.
Classifier modelling
The peptide biomarker patterns discovered by WT, cat
score, t-score, BDA or RF were used in SVM, LDA, DDA,
BDA and RF modelling of classifiers for CADD, AMIP
and ACD. While in LDA, DDA, BDA and RF modelling
specific biomarkers were only combined with the directly
related urinary proteomic profiles (e.g. CADD with DIA-
CADU and VASCAB) to model a specific classifier, in
SVM all possible combinations of the specific biomarker
patterns have been used for modelling different classifiers.
This included patterns generated by selecting all peptides
present in either at least three (≥3) or two (≥2) out of the
WT, cat scores, t-score and RF patterns for each diagnos-
tic/prognostic purpose. However, for AMIP no classifier
could be modelled for the WT and t-score due to the low
number, or absence, of significant peptides. Since the
number of biomarkers discovered for AMIP was limited
regardless of the statistical approach, we also generated a
SVM-modelled classifier utilizing a biomarker pattern
including all the biomarkers discovered by the different
statistical approaches. The same was done for ACD.
Based on LIBSVM, three classifiers were built from
the urinary peptidomic dataset for the following multi-
centre cohorts: 1) Patients already diagnosed with
coronary artery disease (CAD). 2) Patients diagnosed
Fig. 2 Identified biomarkers using different statistical approaches. CADD, coronary artery disease diagnosis; AMIP, acute myocardial infarction
prognostication; ACD, combined coronary artery disease diagnosis and outcome (AMI) prognostication
Table 3 Diagnostic performance of classifiers modelled by SVM, DDA, LDA, BDA and RF for CADD
The values shown are the areas under the curve of Receiver Operating Characteristic (ROC) curve analyses
CADD coronary artery disease diagnosis, SVM support vector machine, DDA diagonal discriminant analysis, LDA linear discriminant analysis, BDA binary
discriminant analysis, RF random forests
*P < 0.05 for CADD WT + RF + BDA vs. CADD t-score and CADD ≥ 3
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with acute coronary syndrome (AMI) within 5 years
after sample collection. 3) Patients belonging to the pre-
vious two groups (i.e. CAD and AMI).
Validation of classifiers
All modelled classifiers were validated by assessing the
proteomic validation datasets mentioned in the methods
section (Table 1). The discriminatory power characterized
by the area under the receiver operating characteristics
curve (AUC) for the different classifiers modelled by SVM,
DDA, LDA, BDA and RF based on the biomarkers patterns
for CADD, AMIP and ACD are shown in Table 3, 4 and 5,
respectively. When comparing the performance of classi-
fiers established by different modelling methods utilizing
the same biomarker patterns discovered by either t-score,
cat-score, BDA or RF, no significant differences were ob-
served between classifiers modelled by DDA, LDA, BDA
or RF compared to classifiers modelled by SVM. How-
ever, when comparing the performance of classifiers
established by SVM for AMIP utilizing the different
biomarker patterns discovered by either cat-score, BDA
or RF, the classifier based on the pattern discovered by
BDA was significantly superior (Table 4). Moreover
WT and t-score did not provide a usable pattern at all.
Such superiority of a method was not observed for CADD
and ACD. The classifiers modelled by LIBSVM did, when
applied to the appropriate matched validation cohorts, not
provide superior performance (Table 7).
Of the SVM-modelled classifiers based on the integra-
tion of biomarkers discovered by different computational
approaches for a specific diagnostic approach (CADD,
AMIP or ACD) into combined patterns, only the ones
providing an AUC above 0.65 in respect of their diag-
nostic/prognostic performance are shown. As the AUCs
shown below the dashed lines in Tables 3, 4 and 5 illus-
trate, the discriminatory power of these classifiers was
mostly similar to the performance of classifiers based on
single biomarker patterns. Only for CADD the classifier
based on the pattern combining the patterns of WT,
BDA and RF significantly outperformed some of the
other classifiers (Table 3).
We further assessed the performance of classifiers based
on the integration of biomarkers discovered by different
computational approaches for CADD and AMIP (Fig. 1,
Table 6) as an alternative to the biomarker patterns
discovered for ACD. While we observed trends towards
Table 4 Prognostic performance of classifiers modelled by SVM, LDA, BDA and RF for AMIP
The values shown are the areas under the curve of Receiver Operating Characteristic (ROC) curve analyses
AMIP acute myocardial infarction prognostication, SVM support vector machine, DDA diagonal discriminant analysis, LDA linear discriminant analysis, BDA binary
discriminant analysis, RF random forests, BM biomarker; ≥ 3, biomarkers present in at least 3 out of the 5 biomarker patterns resulting from the different discovery
approaches; ≥ 2, biomarkers present in at least 2 out of the 5 biomarker patterns resulting from the different discovery approaches
* P < 0.05 for AMIP BDA vs. AMIP cat-score, AMIP ≥ 3 and AMIP ≥ 2
Table 5 Diagnostic/prognostic performance of classifiers modelled by SVM, DDA, LDA, BDA and RF for ACD
The values shown are the areas under the curve of Receiver Operating Characteristic (ROC) curve analyses
ACD combined coronary artery disease diagnosis and outcome (AMI) prognostication, SVM support vector machine, DDA diagonal discriminant analysis, LDA linear
discriminant analysis, BDA binary discriminant analysis, RF random forests, BM biomarker; ≥ 3, biomarkers present in at least 3 out of the 5 biomarker patterns
resulting from the different discovery approaches; ≥ 2, biomarkers present in at least 2 out of the 5 biomarker patterns resulting from the different
discovery approaches
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better diagnostic and prognostic performance for CADD,
AMIP and ACD, none of the differences in performance
were significant.
However, independently of the classifier, the discrimin-
atory power in respect of AMI prediction is much better
for the period of 0 to 5 years than the one for the period of
5 to 11 years.
Discussion
The results of this study showed clearly how challenging
the statistical analysis of complex high-dimensional
proteomic datasets for the identification of reliable dis-
ease-associated biomarkers is, even based on only one
outcome variable. This was first illustrated by the
observed differences in the patterns of potential bio-
markers and the resulting low overall overlap between the
biomarker patterns discovered based on WT, t-score, cat-
score, RF and BDA (Fig. 2). The observation that almost
no single statistical computational approach for biomarker
discovery provided a biomarker pattern and thus a disease
classifier that allowed for a robust significantly superior
diagnostic/prognostic classification of patients, further
underlined this. This was true even when taking correla-
tions between peptides into account by selecting bio-
markers based on correlation-adjusted t-scores followed
by classifier modelling by linear discriminant analysis.
Even the integration of biomarkers discovered by different
statistical approaches into master-patterns did not provide
clearly superior classifiers.
Interestingly, the only peptides of the CADD and ACD
biomarker patterns that were detected by all statistical
discovery approaches were fragments of the fibrillar type
I and III collagens. These collagens are part of the extra-
cellular matrix (ECM) surrounding endothelial cells in
the tunica intima of blood vessels walls and contribute
to the composition of the three dimensional network of
vascular smooth muscle cell (VSMC), fibronectin and
proteoglycan-rich layers of the tunica media as well as
the composition of the fibroblast-rich tunica adventitia
[32, 33]. Both, type I and III collagens are further
responsible for the strength and integrity of the fibrous
cap of atherosclerotic plaques and contribute to the
modulation of cellular responses within it [32–34].
Initial accumulation of collagens as part of the fibrotic
remodelling associated atherosclerosis [35, 36] thus
confers stability to the whole plaque. Type I collagen
can thereby comprise approximately 60% of the total
protein content of an atherosclerotic plaque and plays,
in addition to proteoglycans, an active role in lipid re-
tention [34]. Later atherogenic alterations of the ECM
weaken the fibrous cap and thus contribute to plaque
destabilization [34, 37].
Conclusions
In conclusion, our study revealed a very considerable
dependence of peptide biomarker discovery on statistical
computing of urinary peptide profiles while the observed
diagnostic and/or prognostic reliability of classifiers was
widely independent of the modelling approach. This may
however be due to the limited statistical power in classifier
testing. Nonetheless, our study showed that urinary
proteome analysis has the potential to provide valu-
able biomarkers for coronary artery disease mirroring
Table 6 Diagnostic/prognostic performance of classifiers modelled by SVM
Biomarker patterns Biomarker
number
CADD AMIP ACD
0-5 y 5-11 y 0-5 y
CADD t-score + AMIP all BM 123 0.759 0.730 0.681 0.741
CADD BDA + AMIP all BM 93 0.754 0.779 0.636 0.766
CADD WT + RF + BDA + AMIP all BM 111 0.758 0.736 0.645 0.747
The values shown are the areas under the curve of Receiver Operating Characteristic (ROC) curve analyses
CADD coronary artery disease diagnosis, AMIP acute myocardial infarction prognostication, ACD combined coronary artery disease diagnosis and outcome (AMI)
prognostication, SVM support vector machine, DDA diagonal discriminant analysis, LDA linear discriminant analysis, BDA binary discriminant analysis, RF random
forests, BM biomarker; ≥ 3, biomarkers present in at least 3 out of the 5 biomarker patterns resulting from the different discovery approaches; ≥ 2, biomarkers
present in at least 2 out of the 5 biomarker patterns resulting from the different discovery approaches
Table 7 Multi-centre cohort classifiers built from all 5616 peptides and selected features using f-score
Cohort Size (cases/controls) All peptides (5616) Selected peptides
Total Discovery Validation AUC (discovery) Accuracy (validation) Peptide number AUC (discovery) Accuracy (validation)
CAD 101/96 66/66 35/30 0.750 60% 148 0.871 64.6%
AMI in 0–5 y 113/113 75/75 38/38 0.653 63.2% 154 0.873 73.7%
AMI in 5–11 y 144/171 75/75 69/96 0.653 52.1% 154 0.873 61.2%
CVD 214/208 141/140 73/68 0.709 61.7% 651 0.805 71.6%
y years, AUC area under the curve of a Receiver Operating Characteristic (ROC) curve analysis
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especially alterations in the extracellular matrix. It
further shows that for a comprehensive discovery of
biomarkers and thus of pathological information, the
results of different statistical methods should be com-
bined into a master pattern that then can be used for
classifier modelling.
Additional file
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